menu search

PODD / Insulet Corporation: Margins Are On A Diet

Insulet Corporation: Margins Are On A Diet
Insulet Corporation aims to continue to revolutionize the diabetes market. The company has seen strong commercial traction, driven by the Omnipod 5, although operating leverage is still hard to come by. I like the potential of the business, but am fearful about the elevated expectations at this point in time. Read More
Posted: Jun 5 2023, 17:33
Author Name: Seeking Alpha
Views: 111719

PODD News  

Insulet (PODD) stock up 14% on positive earnings and growth forecast

By Invezz
November 3, 2023

Insulet (PODD) stock up 14% on positive earnings and growth forecast

Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company' more_horizontal

Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.

By Barrons
November 3, 2023

Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.

The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier. more_horizontal

Insulet shares rebound after results top estimates

By Market Watch
November 3, 2023

Insulet shares rebound after results top estimates

Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat more_horizontal

Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, more_horizontal

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
November 2, 2023

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal

Insulet Corporation: Still No Bargain

By Seeking Alpha
October 30, 2023

Insulet Corporation: Still No Bargain

Today, we take a look at Insulet Corporation, a mid-cap medical device concern. The company is focused on developing and marketing insulin delivery sy more_horizontal

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think

By Zacks Investment Research
October 25, 2023

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal

Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

By Zacks Investment Research
October 17, 2023

Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measu more_horizontal


Search within

Pages Search Results: